Liquidia Corp Files 8-K for Material Definitive Agreement

TL;DR

Liquidia Corp signed a big deal on 10/27/25. Details TBD.

AI Summary

On October 27, 2025, Liquidia Corporation entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Morrisville, North Carolina, filed this Form 8-K to report this event. The filing does not provide specific details about the agreement or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for Liquidia Corp, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the terms and financial implications introduces uncertainty.

Key Players & Entities

• Liquidia Corporation (company) — Registrant
• October 27, 2025 (date) — Earliest event reported
• Morrisville, North Carolina (location) — Principal executive offices
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $2,000,000 — ay to Vectura (i) an upfront payment of $2,000,000 in connection with the execution of the
• $12,000,000 — development milestone payments of up to $12,000,000 upon achievement of certain development
• $92.5 million — rtain sales milestone payments of up to $92.5 million tied to commercial sales in the Territo

Filing Documents

• tm2529678d1_8k.htm (8-K) — 27KB
• 0001104659-25-104000.txt ( ) — 189KB
• lqda-20251027.xsd (EX-101.SCH) — 3KB
• lqda-20251027_lab.xml (EX-101.LAB) — 33KB
• lqda-20251027_pre.xml (EX-101.PRE) — 22KB
• tm2529678d1_8k_htm.xml (XML) — 4KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. On October 27, 2025 (the "Effective Date"), Liquidia Technologies, Inc., a Delaware corporation ("Liquidia Technologies") and a wholly owned subsidiary of Liquidia Corporation, a Delaware corporation (the "Company"), entered into an exclusive licensing agreement (the "License Agreement") with Vectura Limited, a company incorporated under the laws of England and Wales ("Vectura"), which provided for, among other things, (i) the exclusive right for Liquidia Technologies to develop, manufacture and commercialize for use in the United States (the "Territory") products containing treprostinil, including Liquidia Technologies' L606, administered via Vectura's nebulizer device (the "Device") for treatment in the field of hypertension and interstitial lung diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and (ii) that Vectura shall be responsible for manufacturing and supplying Liquidia Technologies with clinical and commercial supplies of the Device. Under the License Agreement, Liquidia Technologies shall pay to Vectura (i) an upfront payment of $2,000,000 in connection with the execution of the License Agreement, (ii) certain development milestone payments of up to $12,000,000 upon achievement of certain development milestones; (iii) certain sales milestone payments of up to $92.5 million tied to commercial sales in the Territory and (iv) royalty payments with royalty rates ranging in the middle single digits tied to commercial sales in the Territory. The License Agreement also provides Liquidia Technologies with rights of first negotiation to add additional territories and indications during the term thereof as set out in the License Agreement. The License Agreement is effective upon the Effective Date and unless earlier terminated, shall remain in effect on a country-by-country and product-by-product basis until the expiration

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. October 30, 2025 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer